N/A N=5 Adult Stem Cell Therapy in Liver Insufficiency
Liver Cirrhosis
Primary: Number of Participants With Serious Adverse Events Related to Injection — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=95 Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?
Adrenal Insufficiency · Cirrhosis · Spur Cell Anemia
Primary: Number of Participants With Cholesterol Esterification Deficiency — 10; 11 Participants
N/A N=300 Evaluation of the Role of Aflatoxin as an Environmental Risk Factor Attributable to Liver Cancer in Nile Delta
Liver Cancer
Primary: Serum Aflatoxin Level in Liver Cancer Patients — 7.96; 6.10; 4.13 ng\ml
N/A N=48 Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation
Hepatitis C, Chronic · Non-Alcoholic Fatty Liver Disease
Primary: Cholate Shunt Test — 28.0; 37.6; 33.4 SHUNT %
Phase 4 N=96 Hepatic Xenetix-CT Perfusion
Hepatocellular Carcinoma
Primary: Blood Volume (BV) According to Degree of Lesions Differentiation — 15.930; 13.958 mL/100 grams
N/A N=105 Primary Cell Culture of Hepatic Tumorous Cells From Routine Fine-needle Aspiration
Hepatocellular Carcinoma
Primary: Correlation Between the Growth Speeds of the Cultured Cells and the AJCC TNM Stage (7th Eds) at Entering of the Study. — 21; 29; 14; 9 participants — p=< 0.005
N/A N=20 Effect of Intermittent Pedicle Clamping on Hepatocellular Injury During Liver Surgery
Hepatocellular Injury · Blood Loss
Primary: Hepatocellular Damage Reflected by Liver Fatty-acid Binding Protein (L-FABP) Levels — 9097; 11,688 ng*h/mL
Phase 2 N=18 Use of F-652 in Patients With Alcoholic Hepatitis
Alcoholic Hepatitis
Primary: The Number of Subjects With Unexpected Serious Adverse Events. — 0; 0; 0 Participants
N/A N=77 Dose Escalation Study for Primary Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Number of Patients With DLTs — 0; 2; 1; 0 Participants
N/A N=67 Markers of Liver Apoptosis After Anesthesia With Sevoflurane or Propofol
Liver Dysfunction
Primary: Changes in the M30 and M65 Markers Related to the Anesthesia Type — 237.27; 279.97; 427.33; 470.30 U/L
Phase 4 N=10 The Effect of High Dose Vitamin C on the Liver Function in Chronic Hepatitis Patients
Chronic Hepatitis · Chronic Hepatitis C · Chronic Alcoholic Hepatitis
Primary: The Change in Serum Alanine Aminotransferase Level From Baseline to 12 Weeks — 77.5; 105.5 IU/L
Phase 2 N=5 A Phase I/II Safety and Tolerability Dose Escalation Study of Autologous Stem Cells to Patients With Liver Insufficiency
Liver Disease
Primary: Number of Patients Who Tolerated the Maximum Dose — 5 Participants
Phase 3 N=60 A Human Trial to Evaluate the Efficacy and Safety of Fermented Turmeric in Subjects Showing Mild Hepatic Injury
Mild Hepatic Injury
Primary: Changes in ALT(Alanine Transaminase) — 61.08; 55.68; 44.92; 53.82 IU/L
Phase 2 N=25 Human Fetal Liver Cell Transplantation in Chronic Liver Failure
Liver Cirrhosis
Primary: Patient Survival — 5; 6; 4; 10 participants — p=0.4340
N/A N=160 Controlled Attenuation Parameter (CAP) in Liver Allografts
Liver Transplant · Liver Steatosis · Liver Disease
Primary: Controlled Attenuation Parameter (CAP) - Accuracy — 220 dB/m
N/A N=2,600 Chinese CLIF-C Acute-on-Chronic Liver Disease and Liver Failure Study
Liver Failure, Acute on Chronic
Primary: 28-day Mortality,28-day Liver-transplantation Free Mortality& 28-day Liver Transplantation Rate — 74; 124; 74 Participants
Phase 3 N=230 Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients
Hepatocellular Carcinoma
Primary: Recurrence Free Survival(RFS) — 44.0; 30.0 months — p=0.01
N/A N=34 Transient Elastography in Autoimmune Hepatitis
Liver Cirrhosis
Primary: Sensitivity and Specifity of Transient Elastography in Detection of Liver Cirrhosis — 0.83; 1.00; 1.00; 0.97 Probability
Phase 2 N=44 Acetaminophen for the Reduction of Oxidative Injury in Severe Sepsis
Severe Sepsis
Primary: F2-isoprostanes After 72 Hours of Acetaminophen or Placebo — 33.4; 40.15 pg/mL — p=0.353
Phase 1 N=24 A Hepatic Impairment Study for PF-04965842.
Hepatic Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) for PF-04965842 — 1352; 1276; 1426 nanogram per milliliter (ng/mL)
N/A N=40 Noninvasive Biomarkers of Metabolic Liver Disease 1.1
Nonalcoholic Steatohepatitis · Nonalcoholic Fatty Liver
Primary: Evaluation of Pooled Different-day, Different-operator Reproducibility of Shear Wave Speed Measurements — 30.7 Reproducibility coefficient (in %)
Phase 2 N=47 Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
Hepatocellular Carcinoma · Liver Cancer
Primary: Median Radiographic Time to Progression (TTP) Calculated From Treatment Initiation to First Evidence of Disease Progression or Last Follow-up. — 6.7 months
N/A N=24 Conditionally Increased Output (CIO) Enhanced Ultrasound System
Nonalcoholic Fatty Liver · Nonalcoholic Steatohepatitis · Fatty Liver
Primary: Mean Difference in Aspartate Transaminase (AST) Value in U/L Unit Between Pre-imaging and day7 Post-imaging — -0.5 international units per liter
Phase 2 N=60 Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC
Hepatocellular Carcinoma
Primary: Progression-Free Survival(PFS) — 5.7; 2.7 months — p=<0.001
N/A N=28 Chronic Liver Disease in Urea Cycle Disorders
Urea Cycle Disorder
Primary: Liver Stiffness as Measured by Shear Wave Elastography — 13; 14 Participants
Phase 2 N=47 Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury
Acute Liver Failure · Acute Liver Injury
Primary: Number of Participants That do Not Tolerate the Administered Dose and Had Grade 3 or 4 Treatment Emergent Adverse Events as a Measure of Safety and Tolerability — 0; 0…
Phase 2 N=53 Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver Disease (NAFLD)
Primary: Change in Intrahepatic Lipid Content Between Baseline and 6 Months as Measured by 1H-magnetic Resonance Spectroscopy (1H-MRS). Endpoints Were Assessed at Baseline and 6…
N/A N=12 The Effect of HIT in Patients With Non-alcoholic Fatty Liver Disease/Steatohepatitis
Non-alcoholic Steatohepatitis · Non-alcoholic Fatty Liver Disease
Primary: Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) — 6.9; 9.6; 7.0 units on a scale — p=0.474
N/A N=25 Postoperative Heme Oxygenase Induction and Carbon Monoxide Production as a Novel Method to Assess Hepatic Regeneration and Predict Hepatic Related Morbidity After Partial Hepatectomy
Liver Cancer
Primary: CO Output (Ppm) — 2.03 ppm
N/A N=402 HCC Screening Using DNA Methylation Changes in ctDNA
Hepatocellular Carcinoma
Primary: Calculation of M Scores and HCC Probability Scores — 1.113; 1.159; 1.797; 1.707 units on a scale